Preparing for China · patient guide

Multiple myeloma care: what to clarify before you commit

Before committing to multiple myeloma care in China, clarify four things: the confirmed diagnosis and disease stage, which treatment line and regimen the treating haematologist proposes, whether the specific medicines and tests are actually available at that hospital, and what the written plan and fee scope include. A records-based review can inform questions, but only the treating hospital decides suitability and acceptance.

Go to the practical guidance ↓
AI illustration: A desk with a notebook, pen, blue folders, a glass of water, a potted plant, and a stack of books near a window with a traditional building outside.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Start with the diagnosis, not the destination

Multiple myeloma is a cancer of plasma cells, and treatment decisions depend on more than the name of the disease. The treating haematologist needs to know whether the diagnosis is confirmed, what the current disease phase is, what treatment has already been given, and how the patient is responding. Two patients both labelled 'multiple myeloma' can be at very different points, and the same label does not imply the same regimen.

This is why the first thing to clarify is not which hospital to approach but what the current clinical picture actually is. Ask the current team to summarise the diagnosis in writing: the type of myeloma, the stage or risk information they use, the treatment history with dates and responses, and any complications such as kidney problems, bone disease or infections that affect planning. That summary becomes the basis for any meaningful conversation about care in China.

Be cautious with any plan built only on a diagnosis name. A hospital cannot responsibly indicate whether it can help, or what it would propose, without the records that describe this patient's disease. If a service offers to 'arrange myeloma treatment' before seeing those records, treat that as an enquiry step rather than a clinical plan.

Which treatment line and regimen is being proposed

Multiple myeloma treatment is not one procedure. It can involve combinations of medicines, and for some patients stem cell transplantation is considered. The choice depends on the individual's disease, fitness, prior treatments and goals. So the practical question for any hospital is specific: which line of treatment are they proposing, with which regimen, and why that regimen for this patient?

Ask the treating team to state this in writing. A useful reply names the proposed medicines, the intended schedule, what monitoring is needed, and what alternatives were considered. If the reply is general — 'we will assess and decide' — that may be honest at an early stage, but it is not yet a plan you can compare or budget around.

This matters especially for patients who have already had treatment elsewhere. Later lines of myeloma therapy can depend on which medicines have already been used and how the disease responded. The receiving haematologist needs that history to judge whether a proposed approach is appropriate. Do not assume that a regimen used for one patient applies to another, and do not treat a remote opinion as confirmation that a particular treatment will be given.

Medicine and test availability: ask, do not assume

A common reason patients look abroad is access to specific medicines or tests. The honest position is that availability varies by hospital and changes over time, and it should be confirmed for the named hospital rather than assumed from a drug's general approval status. Ask directly whether the proposed medicines are available at that hospital, and whether any would need to be obtained another way.

The same applies to the tests that guide myeloma care, such as blood and urine tests, imaging and bone marrow assessment. Ask which tests the hospital would repeat, which existing results it would accept, and how long results take. These are questions for the provider; do not rely on general statements about what is 'usually' available in China.

Prescribing, dispensing and stock decisions belong to licensed clinicians and the relevant pharmacy or provider. A coordinator does not decide them. If a medicine is central to the plan, get the hospital's own written confirmation before making travel commitments, and ask what happens if it is unavailable at the planned time.

Records to prepare and what a review can and cannot do

A records-based review can help a patient and family understand the options and prepare better questions, but it does not establish hospital acceptance, final eligibility or that a particular treatment will be available. Keep that distinction clear when deciding how much to invest before travelling.

Gather the records that describe the disease and its course: pathology and laboratory reports confirming the diagnosis, blood and urine results over time, imaging reports, bone marrow reports, treatment records with dates and responses, and a current medication list. A short summary of the patient's main question helps too. After first contact, the team can explain how to share records securely; do not send passport numbers, card details or a complete archive through an initial enquiry form.

Ask the receiving clinician which records are essential and which can follow. If something is missing, the useful step is to clarify the limits of the review and request the relevant documents, not to assume a clinician can work around gaps. An initial enquiry with ChinaSpecialistCare is free and asks for a brief summary; a proxy consultation, where a doctor takes records to a hospital specialist while the patient stays at home, is optional and not a prerequisite for care.

Costs, scope and what the written quote should cover

Myeloma care involves many components — consultations, tests, medicines, possible procedures, monitoring and follow-up — and the total depends on the regimen and the hospital. No responsible estimate can be given from a diagnosis name alone. Ask for an individual, records-based estimate that states what is included and what is not.

Separate the hospital's charges from any coordination fees. Hospital consultations, tests, treatment, medicines and rooms are paid to the hospital or relevant provider; ChinaSpecialistCare's coordination fees are separate and are not offset against later hospital bills. Ask the named provider what its actual written quote includes rather than relying on general assumptions about billing.

For planning, ask the hospital to break the estimate down by phase: assessment, the proposed treatment course, monitoring, and any procedure. Ask what could change the estimate and how additional costs would be communicated. If a figure is offered without a stated scope, treat it as indicative only.

Practical questions before you commit to travel

Before booking anything, get written answers to a short set of questions. Which haematologist or team would take responsibility for this patient? What is the proposed treatment line and regimen, and what monitoring does it require? Which medicines and tests are confirmed available at that hospital? What records are still needed, and what would the review conclude at this stage? What does the written estimate cover, and what could change it?

Also ask about the practical shape of care: how many visits or admissions the plan involves, how communication in English will be handled, and who to contact if the patient becomes unwell before or during travel. These are questions to confirm with the provider, not facts to assume. If the patient has worsening symptoms, urgent local assessment takes priority over overseas planning.

A sensible next step is a free initial case review: send a brief summary of the diagnosis, treatment history and the main question, and the team will identify what is missing and suggest the relevant next step. That is not a diagnosis or a promise of acceptance, and the hospital decides suitability. You can also read the multiple myeloma treatment reference for background before framing your questions.

Related treatment reference

Sources & scope of this guide

References and official service information relevant to this guide.

  1. procedures
  2. Related treatment reference
  3. NCI: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment
  4. NICE guideline NG35: Myeloma – diagnosis, treatment and management

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.